Literature DB >> 23564333

Substantia nigra hyperechogenicity in healthy controls: a [¹⁸Fluoro] Dopa-PET follow-up study.

Ute Schroeder1, Stefanie Behnke, Hans-Georg Buchholz, Klaus Fassbender, Matthias Schreckenberger, Daniela Berg.   

Abstract

In order to assess nigrostriatal function over time in healthy subjects with substantia nigra hyperechogenicity (SN+) believed to be at higher risk for Parkinson's disease (PD), ten healthy SN+ subjects underwent [(18)Fluoro] Dopa positron emission tomography (PET) twice-at baseline and after a mean of 7.3 years. Neurological examination took place at study inclusion followed by a structured telephone interview focusing on early Parkinsonian symptoms at the time point of second PET study and 3.5 years later. The [(18)Fluoro] Dopa uptake remained unchanged in eight of ten participants. In the other two subjects marked unilateral reduction of putaminal [(18)Fluoro] Dopa uptake ratios appeared over the time, followed by complaints of a clinically manifest PD in one. We suggest that the progressive pathological PET findings in 20 % and PD conversion in 10 % of our cohort may be in accordance with the presumed proportion of SN+ individuals eventually developing PD based on SN+ prevalence of 10 % within the healthy population, being ten times higher than PD prevalence in the age of over 60 years. Our findings hint towards a significance of SN+ indicating a high risk for PD in some extrapyramidally healthy SN+ individuals.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23564333     DOI: 10.1007/s00415-013-6904-4

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  7 in total

1.  Hyperechogenicity of the substantia nigra in healthy controls is related to MRI changes and to neuronal loss as determined by F-Dopa PET.

Authors:  S Behnke; U Schroeder; U Dillmann; H G Buchholz; M Schreckenberger; G Fuss; W Reith; D Berg; C M Krick
Journal:  Neuroimage       Date:  2009-06-01       Impact factor: 6.556

2.  The striatal dopaminergic deficit is dependent on the number of mutant alleles in a family with mutations in the parkin gene: evidence for enzymatic parkin function in humans.

Authors:  Rüdiger Hilker; Christine Klein; Katja Hedrich; Laurie J Ozelius; Peter Vieregge; Karl Herholz; Peter P Pramstaller; Wolf Dieter Heiss
Journal:  Neurosci Lett       Date:  2002-04-19       Impact factor: 3.046

3.  Vulnerability of the nigrostriatal system as detected by transcranial ultrasound.

Authors:  D Berg; G Becker; B Zeiler; O Tucha; E Hofmann; M Preier; P Benz; W Jost; K Reiners; K W Lange
Journal:  Neurology       Date:  1999-09-22       Impact factor: 9.910

Review 4.  Transcranial sonography in the premotor diagnosis of Parkinson's disease.

Authors:  Stefanie Behnke; Ute Schröder; Daniela Berg
Journal:  Int Rev Neurobiol       Date:  2010       Impact factor: 3.230

5.  Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism.

Authors:  F J Vingerhoets; B J Snow; C S Lee; M Schulzer; E Mak; D B Calne
Journal:  Ann Neurol       Date:  1994-11       Impact factor: 10.422

6.  Substantia nigra echogenicity is normal in non-extrapyramidal cerebral disorders but increased in Parkinson's disease.

Authors:  U Walter; M Wittstock; R Benecke; D Dressler
Journal:  J Neural Transm (Vienna)       Date:  2002-02       Impact factor: 3.575

7.  Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury.

Authors:  Daniela Berg; Wolfgang Roggendorf; Ute Schröder; Rüdiger Klein; Thomas Tatschner; Peter Benz; Oliver Tucha; Michael Preier; Klaus W Lange; Karlheinz Reiners; Manfred Gerlach; Georg Becker
Journal:  Arch Neurol       Date:  2002-06
  7 in total
  2 in total

Review 1.  Advances in markers of prodromal Parkinson disease.

Authors:  Ronald B Postuma; Daniela Berg
Journal:  Nat Rev Neurol       Date:  2016-10-27       Impact factor: 42.937

Review 2.  Neuroimaging in pre-motor Parkinson's disease.

Authors:  Thomas R Barber; Johannes C Klein; Clare E Mackay; Michele T M Hu
Journal:  Neuroimage Clin       Date:  2017-04-21       Impact factor: 4.881

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.